Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Psychopharmacol Bull ; 52(3): 72-80, 2022 06 27.
Artículo en Inglés | MEDLINE | ID: mdl-35815178

RESUMEN

Buprenorphine and naloxone (Suboxone) is a combination medication-assisted treatment (MAT) for opioid use disorder. MAT withdrawal-induced psychosis is a rare clinical presentation. To our best knowledge, only three reports have summarized the characteristic manifestations of buprenorphine withdrawal psychosis, yet all of them were male. In this case report, we present a 41-year-old female patient with bipolar disorder and comorbid substance use disorder who developed new-onset psychosis and relapse of manic symptoms following abrupt discontinuation of Suboxone. Manic and psychotic symptoms remitted after a short-term hospitalization with the treatment of an antipsychotic and a mood stabilizer. In addition to discussing this case presentation and treatment approach, we review existing literature and discuss possible underlying mechanisms to enhance understanding of this clinical phenomenon.


Asunto(s)
Antipsicóticos , Trastorno Bipolar , Buprenorfina , Trastornos Psicóticos , Síndrome de Abstinencia a Sustancias , Adulto , Antipsicóticos/uso terapéutico , Trastorno Bipolar/tratamiento farmacológico , Buprenorfina/efectos adversos , Combinación Buprenorfina y Naloxona/uso terapéutico , Femenino , Humanos , Masculino , Naloxona/efectos adversos , Trastornos Psicóticos/tratamiento farmacológico , Síndrome de Abstinencia a Sustancias/tratamiento farmacológico , Síndrome de Abstinencia a Sustancias/etiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...